On June 24, 2022, Axsome Therapeutics, Inc. received from the U.S. Food and Drug Administration (the FDA) proposed labeling for the Company's AXS-05 product candidate with respect to its New Drug Application (the NDA) for AXS-05 for the treatment of major depressive disorder. The Company is reviewing the proposed labeling and will reply to the FDA to secure final labeling agreement.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
71.17 USD | -2.61% | +2.09% | -10.58% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-10.58% | 3.37B | |
-2.86% | 87.31B | |
+3.95% | 40.86B | |
-21.94% | 29.36B | |
+54.37% | 24.49B | |
-5.41% | 17.31B | |
-44.23% | 11.26B | |
-17.60% | 11.62B | |
-13.96% | 11.31B | |
+7.12% | 8.31B |
- Stock Market
- Equities
- AXSM Stock
- News Axsome Therapeutics, Inc.
- Axsome Therapeutics, Inc. Receives from the U.S. Food and Drug Administration